Tigecycline

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intra-Abdominal Infections

Conditions

Intra-Abdominal Infections, Skin Disease, Infectious, Soft Tissues Infections

Trial Timeline

Aug 1, 2008 → Dec 1, 2010

NCT ID

NCT00827541

About Tigecycline

Tigecycline is a pre-clinical stage product being developed by Pfizer for Intra-Abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00827541. Target conditions include Intra-Abdominal Infections, Skin Disease, Infectious, Soft Tissues Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01560143	Approved	Completed	Mar 1, 2012	May 1, 2012	Obesity
NCT01401023	Pre-clinical	Completed	Jul 1, 2011	Jul 1, 2013	Diarrhea
NCT01072539	Pre-clinical	Completed	May 1, 2010	Apr 1, 2015	Complicated Skin and Skin Structure Infections
NCT00827541	Pre-clinical	Completed	Aug 1, 2008	Dec 1, 2010	Intra-Abdominal Infections
NCT00575094	Phase 3	Completed	Nov 1, 2007	Mar 1, 2008	Community-Acquired Infections
NCT00419991	Approved	Completed	Jan 1, 2007	May 1, 2008	Staphylococcal Infections
NCT00406237	Phase 1	Completed	Dec 1, 2006	Mar 1, 2009	Liver Cirrhosis, Biliary
NCT00488488	Pre-clinical	Completed	Nov 1, 2006	Mar 1, 2010	Infection
NCT00376324	Phase 1	Completed	Sep 1, 2006	Oct 1, 2008	Healthy Subjects
NCT00488306	Approved	Completed	Aug 1, 2006	Aug 1, 2007	Abdominal Abscess
NCT00488761	Approved	Completed	Jul 1, 2006	Aug 1, 2007	Skin Diseases, Infectious
NCT00136201	Phase 3	Completed	Nov 1, 2005	Dec 1, 2006	Abdominal Abscess
NCT00205816	Phase 3	Completed	Jan 1, 2004	Nov 1, 2005	Bacterial Infections
NCT00079989	Phase 3	Completed	Dec 1, 2003	Nov 1, 2005	Gram-Negative Bacterial Infections
NCT00079885	Phase 3	Completed	Nov 1, 2003	Jul 1, 2005	Community Acquired Pneumonia
NCT00079976	Phase 3	Completed	Oct 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00081744	Phase 3	Completed	Nov 1, 2002	Aug 1, 2004	Gram-Positive Bacterial Infections
NCT00600600	Phase 2	Completed	Apr 1, 2002	Dec 1, 2010	Mycobacterium Abscessus Lung Disease

Competing Products

20 competing products in Intra-Abdominal Infections

See all competitors

Product	Company	Stage	Hype Score
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	77
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	77
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	76
Tigecycline + Imipenem/cilastatin	Pfizer	Approved	84
ceftazidime/NXL104 + metronidazole + meropenem	Pfizer	Phase 2	51
ATM-AVI + Metronidazole	Pfizer	Phase 2	51
Tigecycline (Tygacil)	Pfizer	Pre-clinical	22
Ceftazidime -avibactam + Meropenem + Metronidazole	Pfizer	Phase 2	51
PF-06947386 + Metronidazole	Pfizer	Phase 3	76
CAZ-AVI + Metronidazole + Meropenem	Pfizer	Phase 3	76
ATM-AVI + MTZ + MER + COL	Pfizer	Phase 3	76

Other Products from Pfizer